Journal of Clinical Immunology

, Volume 26, Issue 1, pp 65–72

Health-Related Quality of Life and Treatment Satisfaction in North American Patients with Primary Immunedeficiency Diseases Receiving Subcutaneous IgG Self-Infusions at Home

Authors

    • Section of Clinical Immunology, Department of Laboratory MedicineKarolinska Institutet at Karolinska University Hospital
    • M96, Section of Clinical Immunology, Department of Laboratory MedicineKarolinska Institutet at Karolinska University Hospital
  • Peter Kiessling
    • Clinical Research, ZLB Behring GmbH
  • Melvin Berger
    • Division of Allergy, Immunology and RheumatologyRainbow Babies and Children's Hospital
  • Sudhir Gupta
    • Division of Basic and Clinical Immunology, Department of MedicineUniversity of California
  • Leman Yel
    • Division of Basic and Clinical Immunology, Department of MedicineUniversity of California
  • Chaim M. Roifman
    • The Hospital for Sick Children
  • Ann Gardulf
    • Section of Clinical Immunology, Department of Laboratory MedicineKarolinska Institutet at Karolinska University Hospital
  • Florian Eichmann
    • Kendle International Inc.
  • Stefan Haag
    • Clinical Research, ZLB Behring GmbH
  • Cordula Massion
    • Department of BiostatisticsAccovion GmbH
  • Hans D. Ochs
    • Department of PediatricsUniversity of Washington
Article

DOI: 10.1007/s10875-006-8905-x

Cite this article as:
Nicolay, U., Kiessling, P., Berger, M. et al. J Clin Immunol (2006) 26: 65. doi:10.1007/s10875-006-8905-x

Abstract

The lifelong IgG replacement therapy for patients with primary immunedeficiencies (PIDD) may be provided by intravenous (IVIG) or by subcutaneous IgG (SCIG) infusions. We investigated the impact of weekly SCIG self-infusions at home on the health-related quality of life, treatment satisfaction, and preferences in patients treated with IVIG at the hospital/doctor's office (Group A) or at home (Group B) before the study started. Forty-four adult North American PIDD patients were included in the study, 28 patients in Group A and 16 in Group B. Patients in Group A reported significantly less limitations with their work/daily activities, a significantly improved vitality, and better general health. Treatment satisfaction was significantly improved in Group A. The preference for the subcutaneous route and for home therapy was respectively 81% and 90% in Group A. In Group B, 69% preferred the subcutaneous route and 92% home therapy.

Keywords

Primary immunedeficiency diseasesubcutaneous IgG therapyintravenous IgG therapyhome-therapyquality of lifetreatment satisfaction

Copyright information

© Springer Science + Business Media, Inc. 2006